The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China.
Front Public Health
; 12: 1333487, 2024.
Article
en En
| MEDLINE
| ID: mdl-38699428
ABSTRACT
Background:
Iruplinalkib is a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) with efficacy in patients with ALK-positive crizotinib-resistant advanced non-small cell lung cancer (NSCLC), which is independently developed by a Chinese pharmaceutical company. This study examined the cost-effectiveness of iruplinalkib versus alectinib in the Chinese healthcare setting.Methods:
A partitioned survival model was developed to project the economic and health outcomes. Efficacy was derived using unanchored matching-adjusted indirect comparison (MAIC). Cost and utility values were obtained from the literature and experts' opinions. Deterministic and probabilistic sensitivity analyses (PSA) were carried out to evaluate the model's robustness.Results:
Treatment with iruplinalkib versus alectinib resulted in a gain of 0.843 quality-adjusted life years (QALYs) with incremental costs of $20,493.27, resulting in an incremental cost-effectiveness ratio (ICER) of $24,313.95/QALY. Parameters related to relative efficacy and drug costs were the main drivers of the model outcomes. From the PSA, iruplinalkib had a 90% probability of being cost-effective at a willingness-to-pay threshold of $37,863.56/QALY.Conclusion:
Compared to alectinib, iruplinalkib is a cost-effective therapy for patients with ALK-positive crizotinib-resistant advanced NSCLC.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Piperidinas
/
Carbazoles
/
Análisis Costo-Beneficio
/
Carcinoma de Pulmón de Células no Pequeñas
/
Años de Vida Ajustados por Calidad de Vida
/
Resistencia a Antineoplásicos
/
Crizotinib
/
Quinasa de Linfoma Anaplásico
/
Neoplasias Pulmonares
Límite:
Female
/
Humans
/
Male
/
Middle aged
País/Región como asunto:
Asia
Idioma:
En
Revista:
Front Public Health
Año:
2024
Tipo del documento:
Article
País de afiliación:
China